He’s spending $62 billion to transform a centuries-old Japanese company

Investors weren’t happy when Christophe Weber, the CEO of Japanese pharmaceuticals maker Takeda, said in March 2018 that he would pursue an expensive takeover of Irish rival Shire. Atul Gawande: The surgeon who Buffett, Bezos and Dimon trust to fix health care Michelle Gass: The Kohl’s CEO embraced Amazon More from Risk Takers 2019 Although its recent earnings have been strong, Takeda could face tough times ahead. The company makes drugs that treat cancer, but its pipeline of new products is thin. Takeda also does most of its business in Japan, where regulators are pushing for cheaper generic drugs as the population ages rapidly. “They were in a position where they had to do something dramatic,” said Andersen. Shire will …